Hereditary cancers

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Retrieved on: 
Monday, August 2, 2021
Hereditary cancers, Cancer, Breast cancer, Health, Epidemiology, Risk factors for breast cancer, Prophylactic surgery, Breast cancer screening

For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the markets most accurate hereditary cancer test.

Key Points: 
  • For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the markets most accurate hereditary cancer test.
  • MyRisk with RiskScore offers a breast cancer risk assessment designed to improve patient outcomes and help minimize healthcare disparities.
  • With traditional hereditary cancer tests, approximately 95% of women will test negative for high-risk gene mutations, but still have additional breast cancer risk factors that need to be managed.
  • Working with industry leading researchers, Myriad Genetics assessed data from more than 275,000 women to validate the use of an enhanced method for assessing polygenic breast cancer risk assessments like RiskScore in women across ancestries.

Familial Adenomatous Polyposis Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Cancer, Neoplasms, Clinical medicine, Gastrointestinal cancer, Hereditary cancers, Benign neoplasms, Familial adenomatous polyposis, Polyp, Oncology, Adenoma, FAP, Attenuated familial adenomatous polyposis

The "Familial Adenomatous Polyposis - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Familial Adenomatous Polyposis - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Familial Adenomatous Polyposis (FAP)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Familial Adenomatous Polyposis (FAP), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Familial Adenomatous Polyposis (FAP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis (FAP) epidemiology segmented as the Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis.

Volpara Health Grows Patent Collection with Recently Granted European Protection of Image Quantification

Retrieved on: 
Thursday, July 15, 2021
Patent law, Hereditary cancers, Volpara, Patent portfolio, Breast cancer

LYNNWOOD, Wash., July 15, 2021 /PRNewswire/ -- Volpara has recently been granted another patent by the European Patent Office, raising the total number of patents for the New Zealand-based health tech company to 98.

Key Points: 
  • LYNNWOOD, Wash., July 15, 2021 /PRNewswire/ -- Volpara has recently been granted another patent by the European Patent Office, raising the total number of patents for the New Zealand-based health tech company to 98.
  • This latest patent, effective across 25 European countries, outlines the Volpara method of image quantification, used in multiple instances across the Volpara Breast Health Platform product suite.
  • This patent, together with the entire Volpara patent portfolio, serves to protect all the company's products.
  • Early cancer detection is key to fulfilling the Volpara mission to eliminate late-stage breast cancer and save families from cancer.

Market Leader Eon Rolls Out A First-Of-Its-Kind Breast Software Solution

Retrieved on: 
Tuesday, June 15, 2021
Hereditary cancers, Breast cancer, Empresas Públicas de Medellín, Radiology, Medicine, Health, Applied sciences

DENVER, June 15, 2021 /PRNewswire/ --Denver-based healthtech leader Eon announces the launch of its latest Essential Patient Management (EPM) module, Eon EPM Breast .

Key Points: 
  • DENVER, June 15, 2021 /PRNewswire/ --Denver-based healthtech leader Eon announces the launch of its latest Essential Patient Management (EPM) module, Eon EPM Breast .
  • Eon is the only market available vendor to offer the necessary technology to identify patients with incidental breast findings from radiology examswith 95% accuracyand track their follow-up.
  • Considering only 50% of all incidental breast patients are screening-eligible, the incidental identification and patient management capabilities of EPM Breast set it apart as healthcare's only software option for a comprehensive breast program.
  • Eon EPM Breast is the latest EPM solution for multiple disease states, including breast, lung, aneurysms, pancreas, thyroid, adrenal, renal, and liver.

LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial

Retrieved on: 
Thursday, June 3, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Organic compounds, PARP inhibitors, Chemical compounds, Clinical medicine, Lactams, Olaparib, Phthalazines, Hereditary cancers, Breast cancer, HER2/neu, Talazoparib, Breast cancer classification

The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials.

Key Points: 
  • The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials.
  • LYNPARZA is not currently approved for the adjuvant treatment of gBRCAm high-risk HER2-negative early breast cancer.
  • PARP inhibitor, LYNPARZA (olaparib) is a targeted treatment option for patients with germline BRCA-mutated HER2-negative metastatic breast cancer.
  • Olaparib as Adjuvant Treatment in Patients with Germline BRCA-mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA).

Genetic Technologies’ COVID-19 Risk Test Now Available in US through Partnership with Infinity BiologiX

Retrieved on: 
Tuesday, June 1, 2021
Medical genetics, Branches of biology, Clinical medicine, Medicine, Hereditary cancers, Biotechnology, Molecular diagnostics, Breast cancer, Cancer, Exact Sciences, Natera

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is an Australian based diversified molecular diagnostics company.

Key Points: 
  • Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is an Australian based diversified molecular diagnostics company.
  • The companys lead products, GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer, are clinically validated risk assessment tests and are first in class.
  • Genetic Technologies is developing a pipeline of risk assessment products based on a world leading technology platform created over the past 10 years.
  • Infinity BiologiX (IBX) is a market-disrupting central laboratory supporting academia, government, and industry.

$26.6 Bn Cancer Diagnostics Markets, 2026 - Growing Focus on Personalized Medicine / Companion Diagnostics / Recommendations for Cancer Screening - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
Health, Oncology, Oncology, Hereditary cancers, Medical specialties, Health, Cancer, Breast cancer, Clinical medicine, Medical genetics

The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5% from 2021 to 2026.

Key Points: 
  • The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5% from 2021 to 2026.
  • Breast cancer segment to register the highest growth in the cancer diagnostics market during the forecast period.
  • Based on the application, the cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and other cancer.
  • The breast cancer segment is projected to witness the highest growth in the cancer diagnostics market during the forecast period.

Oncotech develops AI-powered real-time mobile cancer screening and detection system

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health, Clinical medicine, Hereditary cancers, Histopathology, Prostate cancer, Breast cancer, Cancer, Oncology, Treatment of cancer, Screening, War on Cancer

Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.

Key Points: 
  • Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.
  • The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists.
  • "Conditions currently clinically validated and screened include lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer."
  • The Therapeutic R&D and focus is on Diagnostics (mobile in-time cancer screening technology) and cancer treatment Therapies (breast, uterus, lung, prostate, pancreas, liver and neuroblastoma).

Oncotech develops AI-powered real-time mobile cancer screening and detection system

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health, Clinical medicine, Hereditary cancers, Histopathology, Prostate cancer, Breast cancer, Cancer, Oncology, Treatment of cancer, Screening, War on Cancer

Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.

Key Points: 
  • Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.
  • The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists.
  • "Conditions currently clinically validated and screened include lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer."
  • The Therapeutic R&D and focus is on Diagnostics (mobile in-time cancer screening technology) and cancer treatment Therapies (breast, uterus, lung, prostate, pancreas, liver and neuroblastoma).

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic

Retrieved on: 
Wednesday, May 26, 2021
Medical specialties, Health, Cancer, Oncology, Gynaecological cancer, Breast cancer, Hereditary cancers, Vaccine, Ovarian cancer, Triple-negative breast cancer

Anixa Biosciences holds an exclusive worldwide license from Cleveland Clinic for this vaccine technology.

Key Points: 
  • Anixa Biosciences holds an exclusive worldwide license from Cleveland Clinic for this vaccine technology.
  • The award from the NCI, part of the National Institutes of Health, was made to Cleveland Clinic through the NCI-PREVENT program .
  • Our vision with this technology is to eliminate ovarian cancer worldwide, especially since women who suffer from ovarian cancer tend to have poor outcomes."
  • The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer.